Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 32.1% in December

Century Therapeutics, Inc. (NASDAQ:IPSC) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 325,386 shares, a growth of 32.1% from the December 15th total of 246,333 shares. Based on an average trading volume of 1,916,134 shares, the short-interest ratio is presently 0.2 days. Approximately 0.4% of the shares of the stock are short sold. Approximately 0.4% of the shares of the stock are short sold. Based on an average trading volume of 1,916,134 shares, the short-interest ratio is presently 0.2 days.

Insider Buying and Selling at Century Therapeutics

In other news, insider Chad Cowan acquired 58,060 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was purchased at an average cost of $0.85 per share, for a total transaction of $49,351.00. Following the acquisition, the insider owned 1,045,087 shares of the company’s stock, valued at $888,323.95. This trade represents a 5.88% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Brent Pfeiffenberger acquired 52,000 shares of Century Therapeutics stock in a transaction dated Friday, December 12th. The shares were purchased at an average price of $0.58 per share, for a total transaction of $30,160.00. Following the completion of the transaction, the chief executive officer directly owned 3,322,990 shares in the company, valued at approximately $1,927,334.20. The trade was a 1.59% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 145,060 shares of company stock valued at $97,011 and sold 65,987 shares valued at $29,798. 4.37% of the stock is currently owned by insiders.

Institutional Trading of Century Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Prudential Financial Inc. bought a new stake in Century Therapeutics during the second quarter worth about $25,000. Qube Research & Technologies Ltd bought a new stake in shares of Century Therapeutics in the 2nd quarter worth approximately $38,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Century Therapeutics in the 2nd quarter worth approximately $50,000. Raymond James Financial Inc. purchased a new stake in shares of Century Therapeutics in the 2nd quarter worth approximately $51,000. Finally, AQR Capital Management LLC increased its position in Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after buying an additional 86,875 shares in the last quarter. 50.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Leerink Partners reissued a “market perform” rating and set a $2.00 price objective (down previously from $7.00) on shares of Century Therapeutics in a research note on Monday, November 17th. Zacks Research raised shares of Century Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Leerink Partnrs lowered shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $3.40.

Century Therapeutics Price Performance

IPSC traded down $0.13 on Monday, hitting $2.17. The company had a trading volume of 865,084 shares, compared to its average volume of 2,789,345. The stock has a fifty day simple moving average of $0.89 and a 200-day simple moving average of $0.67. The firm has a market capitalization of $189.66 million, a P/E ratio of -6.78 and a beta of 1.72. Century Therapeutics has a 52-week low of $0.34 and a 52-week high of $2.32.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. Equities research analysts expect that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.